Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.48 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | RPA1 | P27694 | 1/20 | 0.41 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16516954 | 0.89 | MAP3K14 (0.49) | ELANEMAP3K14RPA1JMJD6CNR2 | |
| SCHEMBL16517823 | 0.88 | MAP3K14 (0.59) | MAP3K14 | |
| SCHEMBL16516884 | 0.85 | ELANE (0.46) | ELANEMAP3K14RPA1CNR1CNR2 | |
| SCHEMBL16532610 | 0.84 | ELANE (0.40) | ELANEMAP3K14RPA1JMJD6CNR1 | |
| SCHEMBL16516751 | 0.82 | ELANE (0.53) | ELANERPA1F2PLAUCTRB1 | |
| SCHEMBL16547223 | 0.82 | ELANE (0.53) | ELANERPA1F2PLAUCTRB1 | |
| SCHEMBL16517679 | 0.82 | ELANE (0.62) | ELANEMAP3K14RPA1CNR1CNR2 | |
| SCHEMBL16516701 | 0.82 | ELANE (0.53) | ELANEMAP3K14RPA1F2PLAU | |
| SCHEMBL16517333 | 0.81 | ELANE (0.54) | ELANEMAP3K14RPA1F2PLAU | |
| SCHEMBL16517426 | 0.81 | ELANE (0.57) | ELANERPA1F2PLAUCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | ELANE 1188/4885MAP3K14 514/4885RPA1 3870/4885 |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | ELANE 1188/4885MAP3K14 514/4885RPA1 3870/4885 |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | ELANE 1188/4885MAP3K14 514/4885RPA1 3870/4885 |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | ELANE 1188/4885MAP3K14 514/4885RPA1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.